Rush - TMAP Director Going to Singapore

[Guest guest]

http://www.pharmalot.com/2008/09/director-of-controversial-tmap-program-leaves/

Director Of Controversial TMAP Program Leaves 2 Comments By Ed Silverman // September 4th, 2008 // 10:10 am

Rush, the director of a controversial Texas program called T-MAP, which was created to implement a state system for treating psychiatric disorders, has taken a job in Singapore, where he has joined the Duke-NUS Graduate Medical School Singapore as vice dean for clinical sciences. (Look here).

Why is TMAP controversial? The state filed a lawsuit against & ’s Jannsen unit for allegedly using false advertising and improper influence - such as grants, trips and other perks - to get its Risperdal antipsychotic on the now-mandatory adult protocol, the Texas Medication Algorithm Project. Drugmakers also reportedly paid decision makers to promote their meds.

Just last month, Texas officials suspended a similar program tailored for children, called TC-MAP, over fears drugmakers may have given researchers consulting contracts, speaking fees or other payments to help get their products listed on the protocol.

“TMAP and TCMAP proved to be powerful marketing tools for Risperdal…Driven by these gains and revenues, defendants turned to developing a concerted marketing plan to replicate these programs, and the dramatic revenue and market share generated by TMAP and its progeny in other states,” the lawsuit states, according to The Daily Texan.

The research is state-funded but also includes money from private sponsors. The Wood Foundation donated $2.4 million for the initial creation of the TMAP project, according to the paper, which also noted the program received $191,183 from Janssen, $146,500 from Pfizer and $103,000 from Lily. "The doctor of the future will give no medicine but will interest his patients in the care of the human frame, in diet and in the cause and prevention of disease." - Edison --- FAIR USE NOTICE: This transmittal may contain copyrighted material which is made available for educational purposes and to advance understanding of human rights, democracy, scientific, moral, ethical, and social justice issues, etc. The sender asserts that this transmittal constitutes a 'fair use' of any such copyrighted material as provided for in Title 17 U.S.C. section 107 of the US Copyright Law. This material is distributed without profit.

[Guest guest]

http://www.pharmalot.com/2008/09/director-of-controversial-tmap-program-leaves/

Director Of Controversial TMAP Program Leaves 2 Comments By Ed Silverman // September 4th, 2008 // 10:10 am

Rush, the director of a controversial Texas program called T-MAP, which was created to implement a state system for treating psychiatric disorders, has taken a job in Singapore, where he has joined the Duke-NUS Graduate Medical School Singapore as vice dean for clinical sciences. (Look here).

Why is TMAP controversial? The state filed a lawsuit against & ’s Jannsen unit for allegedly using false advertising and improper influence - such as grants, trips and other perks - to get its Risperdal antipsychotic on the now-mandatory adult protocol, the Texas Medication Algorithm Project. Drugmakers also reportedly paid decision makers to promote their meds.

Just last month, Texas officials suspended a similar program tailored for children, called TC-MAP, over fears drugmakers may have given researchers consulting contracts, speaking fees or other payments to help get their products listed on the protocol.

“TMAP and TCMAP proved to be powerful marketing tools for Risperdal…Driven by these gains and revenues, defendants turned to developing a concerted marketing plan to replicate these programs, and the dramatic revenue and market share generated by TMAP and its progeny in other states,” the lawsuit states, according to The Daily Texan.

The research is state-funded but also includes money from private sponsors. The Wood Foundation donated $2.4 million for the initial creation of the TMAP project, according to the paper, which also noted the program received $191,183 from Janssen, $146,500 from Pfizer and $103,000 from Lily. "The doctor of the future will give no medicine but will interest his patients in the care of the human frame, in diet and in the cause and prevention of disease." - Edison --- FAIR USE NOTICE: This transmittal may contain copyrighted material which is made available for educational purposes and to advance understanding of human rights, democracy, scientific, moral, ethical, and social justice issues, etc. The sender asserts that this transmittal constitutes a 'fair use' of any such copyrighted material as provided for in Title 17 U.S.C. section 107 of the US Copyright Law. This material is distributed without profit.

[Guest guest]

http://www.pharmalot.com/2008/09/director-of-controversial-tmap-program-leaves/

Director Of Controversial TMAP Program Leaves 2 Comments By Ed Silverman // September 4th, 2008 // 10:10 am

Rush, the director of a controversial Texas program called T-MAP, which was created to implement a state system for treating psychiatric disorders, has taken a job in Singapore, where he has joined the Duke-NUS Graduate Medical School Singapore as vice dean for clinical sciences. (Look here).

Why is TMAP controversial? The state filed a lawsuit against & ’s Jannsen unit for allegedly using false advertising and improper influence - such as grants, trips and other perks - to get its Risperdal antipsychotic on the now-mandatory adult protocol, the Texas Medication Algorithm Project. Drugmakers also reportedly paid decision makers to promote their meds.

Just last month, Texas officials suspended a similar program tailored for children, called TC-MAP, over fears drugmakers may have given researchers consulting contracts, speaking fees or other payments to help get their products listed on the protocol.

“TMAP and TCMAP proved to be powerful marketing tools for Risperdal…Driven by these gains and revenues, defendants turned to developing a concerted marketing plan to replicate these programs, and the dramatic revenue and market share generated by TMAP and its progeny in other states,” the lawsuit states, according to The Daily Texan.

The research is state-funded but also includes money from private sponsors. The Wood Foundation donated $2.4 million for the initial creation of the TMAP project, according to the paper, which also noted the program received $191,183 from Janssen, $146,500 from Pfizer and $103,000 from Lily. "The doctor of the future will give no medicine but will interest his patients in the care of the human frame, in diet and in the cause and prevention of disease." - Edison --- FAIR USE NOTICE: This transmittal may contain copyrighted material which is made available for educational purposes and to advance understanding of human rights, democracy, scientific, moral, ethical, and social justice issues, etc. The sender asserts that this transmittal constitutes a 'fair use' of any such copyrighted material as provided for in Title 17 U.S.C. section 107 of the US Copyright Law. This material is distributed without profit.

[Guest guest]

http://www.pharmalot.com/2008/09/director-of-controversial-tmap-program-leaves/

Director Of Controversial TMAP Program Leaves 2 Comments By Ed Silverman // September 4th, 2008 // 10:10 am

Rush, the director of a controversial Texas program called T-MAP, which was created to implement a state system for treating psychiatric disorders, has taken a job in Singapore, where he has joined the Duke-NUS Graduate Medical School Singapore as vice dean for clinical sciences. (Look here).

Why is TMAP controversial? The state filed a lawsuit against & ’s Jannsen unit for allegedly using false advertising and improper influence - such as grants, trips and other perks - to get its Risperdal antipsychotic on the now-mandatory adult protocol, the Texas Medication Algorithm Project. Drugmakers also reportedly paid decision makers to promote their meds.

Just last month, Texas officials suspended a similar program tailored for children, called TC-MAP, over fears drugmakers may have given researchers consulting contracts, speaking fees or other payments to help get their products listed on the protocol.

“TMAP and TCMAP proved to be powerful marketing tools for Risperdal…Driven by these gains and revenues, defendants turned to developing a concerted marketing plan to replicate these programs, and the dramatic revenue and market share generated by TMAP and its progeny in other states,” the lawsuit states, according to The Daily Texan.

The research is state-funded but also includes money from private sponsors. The Wood Foundation donated $2.4 million for the initial creation of the TMAP project, according to the paper, which also noted the program received $191,183 from Janssen, $146,500 from Pfizer and $103,000 from Lily. "The doctor of the future will give no medicine but will interest his patients in the care of the human frame, in diet and in the cause and prevention of disease." - Edison --- FAIR USE NOTICE: This transmittal may contain copyrighted material which is made available for educational purposes and to advance understanding of human rights, democracy, scientific, moral, ethical, and social justice issues, etc. The sender asserts that this transmittal constitutes a 'fair use' of any such copyrighted material as provided for in Title 17 U.S.C. section 107 of the US Copyright Law. This material is distributed without profit.